CAMBRIDGE, Mass. January 10, 2020 – Vaxess Technologies, an innovative biotechnology company developing a pipeline of therapeutics and vaccines on the MIMIX™ smart release system, announced that it will present at the Biotech Showcase™ 2020, on Wednesday, January 15 at 10:00AM PST at the Hilton San Francisco Union Square.
During the presentation, CEO Michael Schrader, will introduce the expansion of Vaxess’ MIMIX™ smart release patch technology into a new oncology specific program. MIMIX™, which previously focused on activating the immune system to combat infectious diseases, will now enable new treatment approaches for a range of cancers, starting with skin and oral cancers, then expanding to breast cancer and beyond. Using proprietary sustained release technology, MIMIX™ uses the body’s own immune system to stimulate powerful responses that fight diseases from influenza to cancer.
Further announcements include the appointment of industry experts, Dennis Giesing, Ph.D. and Robert Mashal, M.D, as advisers. Giesing has previous experience in a variety of senior scientific and leadership roles within large pharmaceutical companies and currently serves as Chief Scientific Officer at Taris Biomedical, recently acquired by J&J for their sustained, intra-bladder cancer therapeutic delivery system. Mashal has a robust professional background in both business and cancer drug development from a multitude of executive positions at venture capital firms and pharmaceutical companies and currently acts as the head of strategy at Sanofi’s oncology group.
The company has undergone a major website redesign to not only accommodate the addition of the oncology program, but also to illustrate the updated design of the MIMIX™ technology and its capacity to redefine the therapeutic experience. With just minutes of wear-time, MIMIX™ enables sustained release of treatments from minutes to months, in a shelf-stable and user-friendly, needle-free format.
ABOUT Vaxess Technologies
Vaxess Technologies is a biotechnology company headquartered in Cambridge, Massachusetts. Formed by founders from Harvard University, the company is developing its proprietary sustained release smart technology originally developed at Tufts University and MIT to deliver radically effective therapies in oncology and infectious disease. Vaxess is utilizing the natural properties of silk fibroin to match the most effective delivery profiles of various medicines and vaccines to redefine the therapeutic experience.
